The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy. (2022)
Attributed to:
Epigenomic Mechanisms of Action of Novel Mutant Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukaemia
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/bjh.17850
PubMed Identifier: 34618358
Publication URI: http://europepmc.org/abstract/MED/34618358
Type: Journal Article/Review
Volume: 196
Parent Publication: British journal of haematology
Issue: 5
ISSN: 0007-1048